2022 World Conference on Lung Cancer (ePosters)-EP05.02-021. An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC

EP05.02-021. An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC

Back to course

Pdf Summary

A phase II study was conducted to investigate the effectiveness and safety of neoadjuvant toripalimab (an anti-PD-1 monoclonal antibody) combined with platinum-doublet chemotherapy in patients with potentially resectable non-small cell lung cancer (NSCLC). The updated data from the study showed promising results.<br /><br />A total of 40 patients with stage III potentially resectable NSCLC were screened, and among the 33 evaluable patients, 90.9% met surgical criteria. All 26 patients who underwent surgery achieved R0 resection. Surgical outcomes showed that 65.4% underwent lobectomy, 23.1% underwent double lobectomy, and 11.5% underwent pneumonectomy. The downstaging of nodal status was observed in patients with N2 at baseline.<br /><br />In terms of efficacy, the pathologic response rate was 57.7%, and the pathological complete response rate was 42.3% in the surgical population. In the surgical population, the median duration of follow-up was 16 months, with 1 and 2-year disease-free survival rates of 89.4% and 72.9%, respectively.<br /><br />No new unexpected adverse events were observed, indicating that the combination therapy was well-tolerated.<br /><br />These updated results further confirm the efficacy and safety of neoadjuvant toripalimab plus platinum-doublet chemotherapy in patients with potentially resectable NSCLC. The study suggests that this treatment regimen could improve survival outcomes in these patients. Further evaluation and validation of these findings are warranted.

Asset Subtitle

Yongchang Zhang

Meta Tag

Speaker Yongchang Zhang

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

phase II study

neoadjuvant toripalimab

anti-PD-1 monoclonal antibody

platinum-doublet chemotherapy

non-small cell lung cancer

NSCLC

potentially resectable

surgical criteria

pathologic response rate

adverse events